The expression of P-glycoprotein (P-gp), encoded by theMDR1 gene, is an independent adverse prognostic factor for response and survival in de novo acute myeloid leukemia (AML). Little is known about MDR1 expression during the development of disease. The present study investigated whether MDR1 gene– related clonal selection occurs in the development from diagnosis to relapsed AML, using a genetic polymorphism of the MDR1 gene at position 2677. Expression and function of P-gp were studied using monoclonal antibodies MRK16 and UIC2 and the Rhodamine 123 retention assay with or without PSC 833. No difference was found in the levels of P-gp function and expression between diagnosis and relapse in purified paired blast samples from 30 patients with AML. Thirteen patients were homozygous for the genetic polymorphism ofMDR1 (n = 7 for guanine, n = 6 for thymidine), whereas 17 patients were heterozygous (GT). In the heterozygous patients, no selective loss of one allele was observed at relapse. Homozygosity for the MDR1 gene (GG or TT) was associated with shorter relapse-free intervals (P = .002) and poor survival rates (P = .02), compared with heterozygous patients. No difference was found in P-gp expression or function in patients with AML with either of the allelic variants of the MDR1 gene. It was concluded that P-gp function or expression is not upregulated at relapse/refractory disease and expression of one of the allelic variants is not associated with altered P-gp expression or function in AML, consistent with the fact that MDR1 gene–related clonal selection does not occur when AML evolves to recurrent disease.

Classic multidrug resistance (MDR) encoded by theMDR1 gene is characterized by expression of P-glycoprotein (P-gp), which acts as a drug efflux pump in the plasma membrane. Expression of MDR1 has been identified as an independent adverse prognostic factor for complete remission (CR) and survival in patients with acute myeloid leukemia (AML), especially in adults.1-11 Little is known about possible changes inMDR1 gene expression during the development to relapse or refractory disease, especially in paired analyses of clinical samples of patients with AML. It is conceivable that MDR1 positive clones develop by clonal selection during chemotherapy or byMDR1 gene activation. This phenomenon has been described for Burkitt lymphoma, in which single allelic MDR1 expression was found to be up-regulated during the development of disease.12 

In the present study, we investigated whether clonal selection of oneMDR1 allele contributes to drug resistance in AML, by studying the genetic polymorphism of the MDR1 gene at position 2677.13 This study was performed in paired samples of patients with AML at time of diagnosis and at first relapse or refractory disease. In addition, an analysis was performed of the expression and function of P-gp. To the best of our knowledge, no previous studies have been reported in which the P-gp levels were measured in the allelic variants of the MDR1 gene.

Patients

Bone marrow samples from 30 patients with AML (9 children, 21 adults) were obtained from the iliac crest at diagnosis and at time of first relapse (n = 27) or refractory disease (n = 3) (Table 1). Written informed consent was obtained from each patient and/or their parents to perform these studies. AML classification, according to the French-American-British (FAB) criteria14 was M1 (n = 8), M2 (n = 11), M4 (n = 2), M5 (n = 7), and M6 (n = 2). Cytogenetic analysis was carried out by standard techniques, and the findings were described according to the international nomenclature.15 Patients with a deletion or loss of chromosome 7 were not included in the study, because of the (possible) loss of one MDR1 gene which is located on 7q21.1, which complicates the analysis of polymorphism in these patients. All patients were treated according to the Helsinki agreement and were included in treatment protocols of the Dutch-Belgian Hemato-Oncology Collaborative Group (protocol HOVON 4/4a resp. HOVON 29) for young adults (n = 17), European Organisation for Research and Treatment of Cancer (EORTC protocol LAM 9) (n = 1) for patients 60 years or older, and the Dutch Childhood Leukemia Study Group (DCLSG: protocol ANLL 87 and 94) (n = 9) for children (younger than 18 years old). After relapse or in case of refractory disease after induction therapy, adults were treated according to the HOVON 30 protocol. The pediatric patients received treatment according to institutional protocols (Table2). For some patients, individual therapy choices were made (Table 1). CR status was defined as normocellular marrow with < 5% blasts in a bone marrow (BM) smear and normal peripheral blood cell counts.

Table 1.

Clinical characteristics of 30 patients with acute myeloid leukemia

PatientExpression ofMDR1
gene polymorphism
(G/T variant)
DiagnosisRelapse/Refractory disese
Age
(years)
FAB
classification
KaryotypeRelapse free
after 1st CR
(months)
Treatment
(at time of relapse/
refractory disease)
Response
(to reinduction)
GT M5 Unfavorable NT  
M6 Neutral 2cdA/Ara-C/Idarubicin No CR 
GT 47 M2 Neutral 50 HOVON30 CR 
55 M2 Neutral — HOVON30 No CR** 
50 M5 Neutral 25 HOVON30 CR 
GT 50 M2 Neutral HOVON30 CR 
GT 62 M1 Unfavorable 31 HOVON30 CR 
GT 61 M1 Neutral 29 HOVON30 No CR 
GT 35 M1 Favorable 12 HOVON30 CR 
10 GT M5 Unfavorable NT  
11 GT 12 M1 Neutral 33 DCLSG ANLL94 CR  
12 GT 37 M1 Neutral 12 HOVON29 CR 
13 GT 57 M4 Neutral NT  
14 46 M5a Neutral NT  
15 GT 67 M2 Neutral EORTC 9 No CR 
16 16 M4eo Favorable HOVON29 CR 
17 GT 19 M5a Neutral 28 HOVON29 No CR 
18 GT 42 M2 Neutral 11 HOVON29 CR 
19 GT M1 Neutral 14 DCLSG ANLL87 No CR 
20 41 M6 Neutral HOVON30 CR 
21 GT 10 M2 Favorable 58 DCLSG ANLL94 CR 
22 63 M2 Neutral 20 NT  
23 M5 Unfavorable 10 DCLSG ANLL87 No CR 
24 GT 27 M2 Neutral 14 HOVON30 CR 
25 34 M5 Neutral — HOVON30 No CR** 
26 GT M1 Neutral 18 DCLSG ANLL87 CR 
27 18 M2 Neutral Mitoxantrone No CR 
28 55 M1 Neutral — HOVON30 No CR** 
29 49 M2 Neutral NT  
30 67 M2 Neutral HOVON30 No CR 
PatientExpression ofMDR1
gene polymorphism
(G/T variant)
DiagnosisRelapse/Refractory disese
Age
(years)
FAB
classification
KaryotypeRelapse free
after 1st CR
(months)
Treatment
(at time of relapse/
refractory disease)
Response
(to reinduction)
GT M5 Unfavorable NT  
M6 Neutral 2cdA/Ara-C/Idarubicin No CR 
GT 47 M2 Neutral 50 HOVON30 CR 
55 M2 Neutral — HOVON30 No CR** 
50 M5 Neutral 25 HOVON30 CR 
GT 50 M2 Neutral HOVON30 CR 
GT 62 M1 Unfavorable 31 HOVON30 CR 
GT 61 M1 Neutral 29 HOVON30 No CR 
GT 35 M1 Favorable 12 HOVON30 CR 
10 GT M5 Unfavorable NT  
11 GT 12 M1 Neutral 33 DCLSG ANLL94 CR  
12 GT 37 M1 Neutral 12 HOVON29 CR 
13 GT 57 M4 Neutral NT  
14 46 M5a Neutral NT  
15 GT 67 M2 Neutral EORTC 9 No CR 
16 16 M4eo Favorable HOVON29 CR 
17 GT 19 M5a Neutral 28 HOVON29 No CR 
18 GT 42 M2 Neutral 11 HOVON29 CR 
19 GT M1 Neutral 14 DCLSG ANLL87 No CR 
20 41 M6 Neutral HOVON30 CR 
21 GT 10 M2 Favorable 58 DCLSG ANLL94 CR 
22 63 M2 Neutral 20 NT  
23 M5 Unfavorable 10 DCLSG ANLL87 No CR 
24 GT 27 M2 Neutral 14 HOVON30 CR 
25 34 M5 Neutral — HOVON30 No CR** 
26 GT M1 Neutral 18 DCLSG ANLL87 CR 
27 18 M2 Neutral Mitoxantrone No CR 
28 55 M1 Neutral — HOVON30 No CR** 
29 49 M2 Neutral NT  
30 67 M2 Neutral HOVON30 No CR 

CR indicates complete remission after 1 or 2 courses of reinduction chemotherapy; No CR, refractory disease at time of relapse, No CR** indicates never CR after diagnosis; NT, not treated for relapse. For karyotypes, unfavorable indicates t(9;22), 11q23 with MLL rearrangements, complex karyotype, 5q-; favorable indicates inv(16), t(15;17) and t(8;21); and neutral indicates normal and other karyotypes.

Table 2.

Cumulative drug doses in the treatment protocols for acute myeloid leukemia

DrugAra-CDNRAdriaAmsaIdaVP16MitoxPred6TGVCRCPCsA
Induction             
 HOVON 4/4A 13 400 135  360  500 50      
 HOVON 29 13 400   360 36 500 50      
 DCLSG ANLL87* 22 400 180 120   1050  1120 2580 1000  
 DCLSG ANLL94* 33 400  120  36 950 20 1120 2520 1000  
Reinduction             
 EORTC 9 6000 90     50      
 HOVON 30      500 50     ±5 mg/kg 
DrugAra-CDNRAdriaAmsaIdaVP16MitoxPred6TGVCRCPCsA
Induction             
 HOVON 4/4A 13 400 135  360  500 50      
 HOVON 29 13 400   360 36 500 50      
 DCLSG ANLL87* 22 400 180 120   1050  1120 2580 1000  
 DCLSG ANLL94* 33 400  120  36 950 20 1120 2520 1000  
Reinduction             
 EORTC 9 6000 90     50      
 HOVON 30      500 50     ±5 mg/kg 

(Total cumulative dose in mg/m2.) Ara-C indicates cytosine arabinoside; Adria, adriamycin; DNR, daunorubicin; Amsa, amsacrine; Ida, idarubicin; VP16, etoposide; Mitox, mitoxantrone; Pred, prednisolone; 6TG, 6-thioguanine; VCR, vincristine; CP, cyclophosphamide; and CsA, cyclosporin A.

*

Indicates + 5× intrathecal Ara-C.

Methods

Patient samples.

Bone marrow aspirates were obtained in heparinized tubes. Mononuclear bone marrow cells (MNCs) were collected by Ficoll Hypaque density gradient centrifugation (density 1.077g/m3) (Pharmacia, Uppsala, Sweden). To obtain purified samples with more than 85% blasts, T-cell depletion and adherence depletion were performed.16 Cells were cryopreserved in Iscoves modified Dulbecco medium (IMDM; Gibco, Paisley, United Kingdom) supplemented with 10% dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany) and 20% fetal calf serum (FCS; Gibco) and stored in liquid nitrogen. On the day of the experiments bone marrow cells were thawed. For flowcytometry experiments, cells were washed and resuspended in IMDM supplemented with 10% FCS and gentamycin at a concentration of 4 × 106 cells/mL. Total RNA was isolated using Trisolv extraction (Biotecx, Houston, TX).

Oligonucleotide hybridization and dotblot analysis.

Both DNA and RNA were used as templates in the polymerase chain reaction (PCR). One microgram of genomic DNA was used as a template in the PCR for 40 cycles to investigate the genetic polymorphism at the DNA level. One microgram of total RNA was reverse transcribed and the cDNA template was subjected to 40 cycles of PCR. The following primers were used as described by Mickley12 13: 5′ 2521 GCAAATCTTGGGACAGGAAT; 3′ RNA, 2796 CTCCTTTCGTGTGTAGAAAC; 3′, DNA,2681CCTTC2687 CACTCAGTTTGATTT.

Reverse transcriptase treatment preceded amplification in order to evaluate RNA expression. All PCR experiments included controls without DNA or RNA. After amplification of 1 μg template, 30% of the PCR product was loaded in each of 2 adjacent wells of a slot-blot apparatus. The Zeta Probe nylon filter (Biorad, Hercules, CA) was cut out into 2 halves and each half was hybridized with a different oligonucleotide. Two 19-bp allele-specific oligonucleotide probes (HMO7 and HMO8) were 5′-phosphorylated with [γ32P]-ATP and T4 polynucleotide kinase. HMO7 and HMO8 cover residues 2667 to 2685 and were used for hybridizations. HMO7 possessess a G at position 2677 and HMO8 contains a T at the same position. Internal controls for hybridization and specificity were included in all experiments. For this purpose, two 30-bp oligonucleotides, designated HMC3 and HMC4, were used. These oligonucleotides cover residues 2656 to 2685 of the MDR1 gene with HMC3 possessing a G at position 2677 and HMC4 a T at the same position. Equal amounts of each control were spotted on both sides of the filter. Because the hybridizations were performed under identical conditions, with probes labeled to similar specific activities, the signals from the control oligonucleotides were similar. For quantification of the hybridization spots, the blots were exposed to a Phosfor Imager screen (Molecular Dynamics, Sunnyvale, CA).

Expression of P-glycoprotein.

For measurement of the expression of P-gp, cells were incubated at room temperature with the monoclonal anti–P-gp antibodies MRK1617 (Kamiya Biomedical, Tukwila, WA) at a concentration of 10 μg/mL and also, in separate tubes, with UIC218(Immunotech, Marseille, France) at a concentration of 12.5 μg/mL or with an isotype-matched mIgG2a control antibody (Sigma, St Louis, MO) at a concentration of 10 μg/mL. Cell-bound antibodies were detected by fluorescein isothiocyanate (FITC)–labeled rabbit antimouse immunoglobulin antibodies (Dako, Glostrup, Denmark). Results are given as the ratio of the mean fluorescence of cells incubated with the anti–P-gp antibody divided by the mean fluorescence of cells incubated with the control mIgG2a antibody. To measure the expression of P-gp in CD34-positive cells, cells were labeled with phyco-erythrin-Cy5–labeled CD34 antibody or a phycoerythrin-Cy5–labeled matched mIgG1 antibody (Immunotech).

Function of P-glycoprotein.

For measurement of the function of P-gp, the fluorescent molecule Rhodamine 123 (Rho 123) (Sigma) was used as a P-gp substrate.19,20 Cells were incubated for 1 hour at 37°C at 5% CO2 in the absence or presence of 2 μM of the P-gp modulator PSC 833 (Novartis, Basel, Switzerland). After this incubation, 200 ng/mL Rho 123 was added to the cells. A sample was taken at t = 0 minutes to correct for background fluorescence and at t = 75 minutes to measure intracellular Rho 123 retention. Results were calculated as the PSC/Rho 123 retention ratio of the mean intracellular Rho 123 fluorescence of cells exposed to PSC 833 divided by the mean intracellular Rho 123 fluorescence of cells not exposed to PSC 833. As controls, the drug-sensitive human myeloma cell line 8226 S and the drug-resistant P-gp expressing variant 8226 D6 cells21 were included in each experiment. Taking all experiments together, the mean ratio of P-gp function of the negative control cell line 8226 S was 0.91 ± 0.07 (mean ± SD). The mean ratio of P-gp function of the positive control cell line 8226 D6 was 7.03 ± 4.69 (mean ± SD).

For analysis of the function of P-gp in CD34-positive cells, cells were labeled with phyco-erythrin-Cy5–labeled CD34 antibody or as a control phycoerythrin-Cy5–labeled mIgG1 antibody (Immunotech). Fluorescence was measured using a FACScalibur flowcytometer (Becton Dickinson, San José, CA). Cells were incubated with 0.1 μM TO-PRO-3 (Molecular Probes, Eugene, OR) to exclude nonviable cells in the fuctional and expression studies.

Statistical analysis.

Expression and functional levels of P-gp, either at diagnosis or at relapse or refractory disease, were compared between subgroups using the Mann-Whitney test in case of 2 subgroups, and the Kruskal-Wallis test in case of 3 subgroups. Moreover, MDR1 expression at relapse or refractory disease was compared with that at diagnosis using the Wilcoxon matched-pairs signed-ranks test, which was restricted to patients with data available both at diagnosis and at relapse or refractory disease. All P values are 2-sided and a significance level α = .05 was used.

Thirty patients with AML were studied at diagnosis and during the course of their disease. Twenty-seven patients developed a relapse after reaching CR with induction chemotherapy. Three patients were primary refractory to induction chemotherapy (Table 1).

Oligonucleotide hybridization and dotblot analysis

Oligonucleotide hybridization studies of position 2677 of theMDR1 gene revealed 7 patients with a G variant, 6 patients with a T variant, and 17 patients with a GT variant. The 17 patients with heterozygous expression at diagnosis also showed GT expression at relapse. In these patients, no up-regulation of either allele was noticed during the development of disease at RNA level. Consequently, in this group of patients no evidence of a MDR1 gene–associated selection of a resistant clone was found.

P-glycoprotein expression and function

MRK16 expression (n = 27) and UIC2 expression (n = 25) revealed no differences in P-gp expression at relapse or refractory disease as compared with diagnosis (P = .14 andP = .22, respectively) (Table3). No difference of MRK16 expression in the CD34-positive subpopulation was found (n = 11) (P = 1.0) in the paired analysis. The analysis of UIC2/CD34 in matched pairs showed a trend to a lower expression level (P = .07) in relapsed/refractory disease as compared with diagnosis, although the number of patients that could be analyzed for UIC2/CD34 was small (n = 8) (Table 3; Figure1C). The CD34 expression was not different at relapse as compared to diagnosis (P = .31).

Table 3.

Paired analysis of P-glycoprotein expression and function in patients with acute myeloid leukemia at diagnosis and relapse/refractory disease

At diagnosisAt relapse and/or refractory diseaseP value
MDR   
MRK16    
 Median 2.16 1.83 .14 
 Range 1.22-7.65 1.02-5.55  
 N 27   
MRK16/CD34+    
 Median 2.77 2.28 1.00 
 Range 1.52-9.27 1.46-9.6  
 N 11   
UIC2    
 Median 2.37 1.74 .22 
 Range 1.47-12.3 0.99-6.39  
 N 25   
UIC2/CD34+    
 Median 3.5 2.42 .07 
 Range 1.51-26.6 0.86-7.34  
 N   
PSC/Rho    
 Median 1.13 1.10 .26 
 Range 0.87-2.11 0.81-2.19  
 N 27   
PSC/Rho/CD34+    
 Median 1.43 1.22 .39 
 Range 0.98-2.7 0.82-3.26  
 N 12   
At diagnosisAt relapse and/or refractory diseaseP value
MDR   
MRK16    
 Median 2.16 1.83 .14 
 Range 1.22-7.65 1.02-5.55  
 N 27   
MRK16/CD34+    
 Median 2.77 2.28 1.00 
 Range 1.52-9.27 1.46-9.6  
 N 11   
UIC2    
 Median 2.37 1.74 .22 
 Range 1.47-12.3 0.99-6.39  
 N 25   
UIC2/CD34+    
 Median 3.5 2.42 .07 
 Range 1.51-26.6 0.86-7.34  
 N   
PSC/Rho    
 Median 1.13 1.10 .26 
 Range 0.87-2.11 0.81-2.19  
 N 27   
PSC/Rho/CD34+    
 Median 1.43 1.22 .39 
 Range 0.98-2.7 0.82-3.26  
 N 12   

For P-gp expression, the monoclonal antibodies MRK 16 and UIC2 were used; for P-gp function, the PSC/Rho 123 retention ratio was used. In samples with greater than 10% CD34 expression, the variables were also evaluated in the CD34+ subfraction of the blasts. TheP values indicate the differences between diagnosis and relapse/refractory disease.

Fig. 1.

P-glycoprotein expression and function in the CD34-positive population of the paired AML patients.

(C) The UIC2 and (B) MRK16 ratios represent the expression of P-gp, and (A) PSC 833/Rho123 represents the function of P-gp. Dx indicates diagnosis; Rel/RD, relapsed/refractory AML. The dotted lines indicate the median values.

Fig. 1.

P-glycoprotein expression and function in the CD34-positive population of the paired AML patients.

(C) The UIC2 and (B) MRK16 ratios represent the expression of P-gp, and (A) PSC 833/Rho123 represents the function of P-gp. Dx indicates diagnosis; Rel/RD, relapsed/refractory AML. The dotted lines indicate the median values.

Close modal

The PSC/Rho 123 retention ratio (n = 27) was not significantly different between diagnosis and relapsed/refractory AML (P = .26). When analyzed in the CD34-positive subpopulation of blasts (n = 12), comparable results were found (P = .39) (Table 3; Figure 1A). No difference was found in P-gp expression (P = .67 for MRK16 expression,P = .82 for UIC2 expression) or PSC/Rho ratio (P = .09) at diagnosis nor at relapse/refractory disease (P values of .42, .67, and .11, respectively) between adults and children.

P-glycoprotein versus MDR1 allelic expression

As the functional meaning of the genetic polymorphism of theMDR1 gene has not been established as yet, we analyzed P-gp in patients with expression of the G, T, and GT variants. The median MRK16 expression ratio was not significantly different in the various allelic variants (P = .72 at diagnosis andP = .34 at relapse). Also, no difference was found with monoclonal antibody UIC2 (P = .81 at diagnosis andP = .25 at relapse) and the PSC/Rho 123 retention ratio (P = .26 at diagnosis, P = .11 at relapse). No difference was found in P-gp expression or function when homozygous patients were compared with heterozygous patients (Table4). Similarly, in the CD34-positive fraction we did not find differences in P-gp expression and function between the different MDR1 allelic variants at diagnosis nor at relapse and/or refractory disease. The results show that there is no difference in P-gp expression and function in AML blast cells between the different specific allelic variants of the MDR1 gene. The therapeutic outcome of patients with the different allelic variants showed a significant difference, that is, homozygosity was associated with a shorter time from diagnosis to relapse (P = .002) and a shorter overall survival from relapse (P = .02) (Figure 2A,B).

Table 4.

Analysis of P-glycoprotein expression and function in the homozygous vs the heterozygous allelic variants of the MDR1 gene at time of relapse/refractory disease

GG or TTGTP value
MDR   
MRK16    
 Median 1.54 2.14 .15 
 Range 1.02-5.45 1.18-5.55  
 N 13 17  
MRK16/CD34    
 Median 1.88 2.68 .22 
 Range 1.49-4.90 1.46-9.6  
 N  
UIC2    
 Median 1.56 2.28 .22 
 Range 1.12-6.39 0.99-5.24  
 N 13 17  
UIC2/CD34    
 Median 1.67 2.72 .10 
 Range 0.86-7.34 1.69-5.15  
 N  
PSC/Rho    
 Median 1.08 1.14 .30 
 Range 0.81-1.85 0.84-2.19  
 N 13 17  
PSC/Rho/CD34    
 Median 1.21 1.42 .40 
 Range 1.07-1.72 0.82-3.26  
 N  
GG or TTGTP value
MDR   
MRK16    
 Median 1.54 2.14 .15 
 Range 1.02-5.45 1.18-5.55  
 N 13 17  
MRK16/CD34    
 Median 1.88 2.68 .22 
 Range 1.49-4.90 1.46-9.6  
 N  
UIC2    
 Median 1.56 2.28 .22 
 Range 1.12-6.39 0.99-5.24  
 N 13 17  
UIC2/CD34    
 Median 1.67 2.72 .10 
 Range 0.86-7.34 1.69-5.15  
 N  
PSC/Rho    
 Median 1.08 1.14 .30 
 Range 0.81-1.85 0.84-2.19  
 N 13 17  
PSC/Rho/CD34    
 Median 1.21 1.42 .40 
 Range 1.07-1.72 0.82-3.26  
 N  

For P-gp expression, the monoclonal antibodies MRK16 and UIC2 were used; for P-gp function, the PSC/Rho 123 retention ratio was used. In samples with more than 10% CD34 expression, the variables were also evaluated in the CD34+ subfraction of the blasts. TheP values indicate the differences between the homozygous and heterozygous patients.

Fig. 2.

Survival of the patients with AML.

Distinguishing patients that are homozygous (GG and TT) from patients that are heterozygous (GT) for the genetic polymorphism of position 2677 of the MDR1 gene. (A) Time from diagnosis until relapse/refractory disease. (B) Overall survival from relapse/refractory disease. N indicates number of patients investigated; O, observed events.

Fig. 2.

Survival of the patients with AML.

Distinguishing patients that are homozygous (GG and TT) from patients that are heterozygous (GT) for the genetic polymorphism of position 2677 of the MDR1 gene. (A) Time from diagnosis until relapse/refractory disease. (B) Overall survival from relapse/refractory disease. N indicates number of patients investigated; O, observed events.

Close modal

Clinical resistance to chemotherapy is a major problem in relapsed and/or refractory AML. MDR1 expression in de novo AML is an adverse prognostic factor for CR and survival.3-7,11,22 It is conceivable that up-regulation of the MDR1 gene is involved in the development of relapse and/or refractory disease, although this has not been investigated in paired analyses of respectable numbers of clinical samples of patients with AML.12 In the present study we analyzed whether clonal selection associated with the MDR1 gene is involved in the development of relapsed AML. This is the first study that examined the allelic expression of MDR1 in AML, using the genetic polymorphism of the MDR1 gene. Our data show that there is no evidence of a MDR1 gene–related clonal selection in the evolution of AML to relapse or refractory disease.

This is consistent with our observation that P-gp expression and function did not increase from diagnosis to relapsed/refractory state. Several studies have reported a higher MDR1 expression at time of relapse as compared to diagnosis.23-29 However, most studies compared patients who were not matched and studies in paired patient samples are scarce and generally they were performed in small numbers of patients. Most studies suggest an identical expression or even lower level of MDR1 in relapsed/refractory AML.29-32 Only the sequential analysis by Wood, who used immunocytochemistry techniques, showed a higher percentage of P-gp–positive samples in 14 relapsed patients with AML as compared with diagnosis.33 In pediatric patients, only 3 case reports are available.25,34,35 Therefore, although many studies have suggested that MDR1 is up-regulated in relapsed and/or refractory AML, sequential studies do not support this theory (Table 5 and Table6). The present analysis, which is the largest paired study in AML thus far, is an attempt to quantify MDR1 expression at genomic and protein level during the development toward resistant disease. In the 9 children and 21 adults studied, we did not find evidence that MDR1, although being a strong prognostic factor at the time of diagnosis, is up-regulated at time of relapse and/or refractory disease in AML. We suggest that similar sequential studies of other mechanisms of drug resistance should be performed in patients with AML during the course of their disease in order to determine which drug resistance proteins are associated with clonal selection at relapse. In these studies it will be important to analyze children and younger adults separately from elderly patients with AML, since different mechanisms might be important in different age groups.6 Until now, the only study that analyzed P-gp expression in a large group of children with AML showed that in contrast to adult AML, MDR1 expression was not of prognostic significance.39 In the present study no difference was found in P-gp expression and function between adults and children.

Table 5.

Review of analyses of MDR1 expression in paired samples of patients with acute myeloid leukemia

AuthorReferenceNumber
of patients
Expression levelMDR1Age categoryMDR1 expression number in relapsed vs de novo AML
Gekeler 35  RNA Children Higher 
Beck 36  RNA Children Higher 
Guerci 26  Protein Adults Higher/equal 
Hart 32  RNA Adults Higher/lower 
Ino 31  21 Protein Adults Equal/lower 
Sato 37  RNA Adults Equal 
Ito 30  10 DNA Adults Equal 
Ito 30 RNA Adults Equal 
Ito 30 10 Protein Adults Higher/lower 
Kaczorowski 34  Protein Children Higher 
List 29  17 Protein Adults Lower 
Marie 24  RNA Adults Higher/equal 
Marie 38  RNA Adults Higher/lower/equal 
Ma 41  Protein Adults Higher/equal 
Musto 23  Protein Adults Higher 
Maslak 27  Protein Adults Higher 
Michieli 28  Protein Adults Higher/lower/equal 
Wood 33  14 Protein Adults Higher 
AuthorReferenceNumber
of patients
Expression levelMDR1Age categoryMDR1 expression number in relapsed vs de novo AML
Gekeler 35  RNA Children Higher 
Beck 36  RNA Children Higher 
Guerci 26  Protein Adults Higher/equal 
Hart 32  RNA Adults Higher/lower 
Ino 31  21 Protein Adults Equal/lower 
Sato 37  RNA Adults Equal 
Ito 30  10 DNA Adults Equal 
Ito 30 RNA Adults Equal 
Ito 30 10 Protein Adults Higher/lower 
Kaczorowski 34  Protein Children Higher 
List 29  17 Protein Adults Lower 
Marie 24  RNA Adults Higher/equal 
Marie 38  RNA Adults Higher/lower/equal 
Ma 41  Protein Adults Higher/equal 
Musto 23  Protein Adults Higher 
Maslak 27  Protein Adults Higher 
Michieli 28  Protein Adults Higher/lower/equal 
Wood 33  14 Protein Adults Higher 
Table 6.

Review of MDR1 expression in acute myeloid leukemia in nonpaired studies

Author
ReferenceNumber of patientsExpression levelAge categoryMDR1 expression in relapsed vs de novo AML
DxRelapse
Beck 36  14 23 RNA Children Higher 
Guerci 26  69 10 Protein Adults Higher 
List 29  21 29 Protein Adults Equal/lower 
Marie 24  21 RNA Adults Equal 
Musto 23  Protein Adults Lower 
Maslak 27  18 19 Protein Adults and children Higher 
Michieli 28  38 21 Protein Adults Higher 
Author
ReferenceNumber of patientsExpression levelAge categoryMDR1 expression in relapsed vs de novo AML
DxRelapse
Beck 36  14 23 RNA Children Higher 
Guerci 26  69 10 Protein Adults Higher 
List 29  21 29 Protein Adults Equal/lower 
Marie 24  21 RNA Adults Equal 
Musto 23  Protein Adults Lower 
Maslak 27  18 19 Protein Adults and children Higher 
Michieli 28  38 21 Protein Adults Higher 

Our study emphasizes that it is important to study MDR1 expression in clinical samples from patients with AML. In many cell lines, including even AML cell lines, MDR expression may be up-regulated as a direct response of cells to antineoplastic drugs. However, it seems apparent that this does not occur in patients with AML.40-48 This is the first analysis of the functional significance of the genetic polymorphism of MDR1 in highly purified samples of AML. P-gp function and expression were similar in any one of the specific allelic variants (G, T, and GT). These findings suggest that the genetic polymorphism of the MDR1 gene (at position 2677) lacks functional importance in AML. However, we found that patients with homozygous expression of the MDR1gene (GG or TT) had a shorter time to relapse and overall survival from relapse/refractory disease than heterozygous patients. This finding warrants further studies on the role of genetic polymorphisms ofMDR1 in AML.

MDR1 expression at diagnosis is a strong adverse prognostic factor in AML. However, our sequential analysis reveals that there is no higher function or expression of P-gp at relapse or refractory disease, and that specific allelic expression is not related to increased P-gp expression or function. Since no loss of a specificMDR1 allele has been observed in these patients with AML,MDR1 gene–related clonal selection plays no role in the development of resistant disease. These data suggest that mechanisms other than MDR1 might be responsible for the development of clinical resistance in these patients.

We thank the Dutch Childhood Leukemia Study Group for bone marrow samples of pediatric patients with AML.

Supported by the Sophia Foundation for Medical Research (SSWO grant 246), the Foundation Pediatric Oncology Centre Rotterdam (Stichting SKOR), and the Kröger Society.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Campos
L
Guyotat
D
Archimbaud
E
et al
Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis.
Blood.
79
1992
473
476
2
Del Poeta
G
Stasi
R
Venditti
A
et al
Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
Leukemia.
8
1994
388
394
3
Del Poeta
G
Stasi
R
Aronica
G
et al
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia.
Blood.
87
1996
1997
2004
4
Leith
CP
Kopecky
KJ
Godwin
J
et al
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study.
Blood.
89
1997
3323
3329
5
Van den Heuvel-Eibrink
MM
van der Holt
B
te Boekhorst
PA
et al
MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia.
Br J Haematol.
99
1997
76
83
6
Van den Heuvel-Eibrink
MM
Sonneveld
P
Pieters
R
The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.
Int J Clin Pharmacol Ther.
38
2000
94
110
7
Willman
CL
The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Semin Hematol.
34
4 suppl 5
1997
25
33
8
Senent
L
Jarque
I
Martin
G
et al
P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Haematologica.
83
1998
783
787
9
Legrand
O
Simonin
G
Zittoun
R
Marie
JP
Both P-gp and MRP contribute to drug resistance in AML.
Blood.
94
1999
1046
1056
10
Legrand
O
Simonin
G
Perrot
JY
Zittoun
R
Marie
JP
P-gp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.
Blood.
91
1998
4480
4488
11
Michieli
M
Damiani
D
Ermacora
A
et al
P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
Br J Haematol.
104
1999
328
335
12
Mickley
LA
Lee
JS
Weng
Z
et al
Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors.
Blood.
91
1998
1749
1756
13
Mickley
LA
Spengler
BA
Knutsen
TA
Biedler
JL
Fojo
T
Gene rearrangement: a novel mechanism for MDR-1 gene activation.
J Clin Invest.
99
1997
1947
1957
14
Bennett
JM
Catovsky
D
Daniel
MT
et al
Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group.
Ann Intern Med.
103
1985
620
625
15
Mitelman
F
ISCN 1991: Guidelines for Cancer Cytogenetics: Supplement to an International System for Human Cytogenetic Nomenclature.
1991
Karger
Basel, Switzerland
16
Lowenberg
B
van Putten
WL
Touw
IP
Delwel
R
Santini
V
Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia.
N Engl J Med.
328
1993
614
619
17
Sugawara
I
Kataoka
I
Morishita
Y
et al
Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.
Cancer Res.
48
1988
1926
1929
18
Mechetner
EB
Roninson
IB
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
Proc Natl Acad Sci U S A.
89
1992
5824
5828
19
Chaudhary
PM
Roninson
IB
Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.
Cell.
66
1991
85
94
20
Ludescher
C
Thaler
J
Drach
D
et al
Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123.
Br J Haematol.
82
1992
161
168
21
Dalton
WS
Durie
BG
Alberts
DS
Gerlach
JH
Cress
AE
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.
Cancer Res.
46
1986
5125
5130
22
Hunault
M
Zhou
D
Delmer
A
et al
Multidrug resistance gene expression in acute myeloid leukemia: major prognostic significance for in vivo drug resistance to induction treatment.
Ann Hematol.
74
1997
65
71
23
Musto
P
Cascavilla
N
Di Renzo
N
et al
Clinical relevance of immunocytochemical detection of multidrug resistance associated P-glycoprotein in hematologic malignancies.
Tumori.
76
1990
353
359
24
Marie
JP
Zittoun
R
Sikic
BI
Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity.
Blood.
78
1991
586
592
25
Beck
WT
Grogan
TM
Willman
CL
et al
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
Cancer Res.
56
1996
3010
3020
26
Guerci
A
Merlin
JL
Missoum
N
et al
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Blood.
85
1995
2147
2153
27
Maslak
P
Hegewisch-Becker
S
Godfrey
L
Andreeff
M
Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Cytometry.
17
1994
84
93
28
Michieli
M
Giacca
M
Fanin
R
Damiani
D
Geromin
A
Baccarani
M
Mdr-1 gene amplification in acute lymphoblastic leukaemia prior to antileukaemic treatment.
Br J Haematol.
78
1991
288
289
29
List
AF
Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
Leukemia.
10
1996
937
942
30
Ito
Y
Tanimoto
M
Kumazawa
T
et al
Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells: sequential analysis of 15 cases at initial presentation and relapsed stage.
Cancer.
63
1989
1534
1538
31
Ino
T
Miyazaki
H
Isogai
M
et al
Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome.
Leukemia.
8
1994
1492
1497
32
Hart
SM
Ganeshaguru
K
Hoffbrand
AV
Prentice
HG
Mehta
AB
Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia.
Leukemia.
8
1994
2163
2168
33
Wood
P
Burgess
R
MacGregor
A
Yin
JA
P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival.
Br J Haematol.
87
1994
509
514
34
Kaczorowski
S
Ochoka
M
Aleksandrowicz
R
Kaczorowska
M
Matysiak
M
Karwacki
M
Expression of P-glycoprotein in children and adults with leukemia: correlation with clinical outcome.
Acute Leukemias V: Experimental Approaches and Management of Refractory Diseases.
Hiddeman
et al
1996
101
107
Springer-Verlag
Berlin, Heidelberg
35
Gekeler
V
Frese
G
Noller
A
et al
Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.
Br J Cancer.
66
1992
507
517
36
Beck
J
Handgretinger
R
Klingebiel
T
et al
Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML.
Leukemia.
10
1996
426
433
37
Sato
H
Preisler
H
Day
R
et al
MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia.
Br J Haematol.
75
1990
340
345
38
Marie
JP
Faussat-Suberville
AM
Zhou
D
Zittoun
R
Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression.
Leukemia.
7
1993
825
831
39
Sievers
EL
Smith
FO
Woods
WG
et al
Cell surface expression of the multidrug resistance P-glycoprotein (P- 170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group.
Leukemia.
9
1995
2042
2048
40
Gekeler
V
Frese
G
Diddens
H
Probst
H
Expression of a P-glycoprotein gene is inducible in a multidrug resistant human leukemia cell line.
Biochem Biophys Res Commun.
155
1988
754
760
41
Ma
DD
Scurr
RD
Davey
RA
et al
Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia.
Lancet.
1
1987
135
137
42
Baas
F
Jongsma
AP
Broxterman
HJ
et al
Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
Cancer Res.
50
1990
5392
5398
43
Goldstein
LJ
Galski
H
Fojo
A
et al
Expression of a multidrug resistance gene in human cancers.
J Natl Cancer Inst.
81
1989
116
124
44
Chaudhary
PM
Roninson
IB
Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.
J Natl Cancer Inst.
85
1993
632
639
45
Gekeler
V
Beck
J
Noller
A
et al
Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.
Ann Hematol.
69(suppl 1)
1994
S19
S24
46
Brock
I
Hipfner
DR
Nielsen
BS
et al
Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.
Cancer Res.
55
1995
459
462
47
Matsumoto
Y
Takano
H
Fojo
T
Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Cancer Res.
57
1997
5086
5092
48
Knutsen
T
Mickley
LA
Ried
T
et al
Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P- glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.
Genes Chromosomes Cancer.
23
1998
44
54

Author notes

M. M. van den Heuvel-Eibrink, Sophia Children's Hospital, Department of Oncology/Hematology, Rm Sp 2429, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands; e-mail:[email protected].

Sign in via your Institution